Ipsen logo

Ipsen(OTC) IPSEY

Market Cap$13.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)+173%
5 Year+74%
1 Year+21%
1 Month-13%
$40.65
+1.26%
+0.50Today
Ipsen last closing stock price
MetricPriceDate
Last closeUSD 40.652026-10-09
Ipsen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.97%USD 41.902026-10-02
1 month-12.57%USD 46.502026-09-09
3 month-14.81%USD 47.722026-07-10
Year to date+13%USD 35.982025-12-31
1 year+20.84%USD 33.642025-10-09
3 year+31.34%USD 30.952023-10-10
5 year+73.85%USD 23.382021-10-08
Since inception+173.36%USD 14.872008-12-12

Ipsen Financials at a Glance

Market Cap

$13.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€7.82B

Net Income (TTM)

€959.69M

EPS (TTM)

$1.80

P/E Ratio

22.49

Dividend

$0.46

Beta (Volatility)

0.16 (Low)

Price

$40.65

Volume

395

Open

$40.65

Previous Close

$40.65

Daily Range

$40.65 - $40.65

52-Week Range

$32.68 - $51.10

Estimated Earnings Date

Feb 11, 2027

IPSEY News

Roche

Exelixis Finally Snags a Licensing Partner for Cometriq

Sean WilliamsMar 1, 2016

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ipsen

Ipsen S.A. is a biopharmaceutical company focused on developing and commercializing innovative medicines in oncology, rare diseases, and neuroscience. With a strong portfolio of products and a commitment to research and development, Ipsen aims to address unmet medical needs globally.

Products and Services
  • Oncology treatments including Somatuline and Cabometyx
  • Rare disease therapies such as Bylvay and Iqirvo
  • Neuroscience products like Dysport for migraine treatment
Growth Outlook
  • Recent quarterly revenue reached €2.3 billion, indicating strong market demand
  • Ongoing clinical trials for innovative therapies may enhance product pipeline
  • Strategic partnerships could expand market reach and accelerate growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of €8.2 billion reflects consistent growth
  • Net income for the latest quarter was €403 million, showcasing profitability
  • Dividend yield of 1.07% indicates a commitment to returning value to shareholders
Ipsen S.A. operates in the healthcare sector, specifically within the drug manufacturing industry, focusing on specialty and generic medications. The company has established a robust presence in oncology, with products like Somatuline and Cabometyx addressing critical health issues. Additionally, Ipsen is actively involved in developing treatments for rare diseases and neurological conditions, which positions it well in niche markets with high growth potential. The growth outlook for Ipsen appears promising, bolstered by recent revenue figures and ongoing clinical trials that may lead to new product introductions. The company's strategic partnerships are also expected to enhance its market presence and drive future growth. Financially, Ipsen has demonstrated resilience, with a solid revenue base and a commitment to profitability, as evidenced by its recent net income figures. Overall, Ipsen S.A. presents a compelling opportunity for investors interested in the biopharmaceutical sector, particularly those looking for companies with a strong focus on innovation and a diverse product portfolio.
AI Generated • Sep 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

5,535

CEO

David G. Loew, MBA

Website

www.ipsen.com

Headquarters

Paris, IF 75015, FR

IPSEY Financials

Key Financial Metrics (TTM)

Gross Margin

67.52%

Operating Margin

30.13%

Net Income Margin

12.67%

Return on Equity

11.33%

Return on Capital

13.78%

Return on Assets

6.87%

Earnings Yield

4.45%

Dividend Yield

1.13%

Payout Ratio

25.71%

Stock Overview

Market Cap

$13.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

330.84M

Volume

395

Avg. Volume

842.462

Financials (TTM)

Gross Profit

€6.08B

Operating Income

€1.46B

EBITDA

€2.89B

Operating Cash Flow

€2.31B

Capital Expenditure

-€860.48M

Free Cash Flow

€1.45B

Cash & ST Invst.

€1.97B

Total Debt

€963.10M

Ipsen Performance Analysis

Ipsen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 3,179,197,3081.8%
20232023-12-31EUR 3,381,189,0486.4%
20242024-12-31EUR 3,678,397,5868.8%
20252025-12-31EUR 4,148,539,68912.8%
Ipsen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-314.0%
Q22025-06-306.3%
Q42025-12-31-4.9%
Q22026-06-3020.5%
Ipsen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 2.05-10.5%
20232023-12-31EUR 2.091.9%
20242024-12-31EUR 1.12-46.3%
20252025-12-31EUR 1.5033.8%
Ipsen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-52.8%
Q22025-06-30192.0%
Q42025-12-31-72.2%
Q22026-06-30337.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€2.22B

+26.7%

Gross Profit

€1.65B

+15.3%

Gross Margin

74.52%

N/A

Market Cap

$13.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.43M

N/A

Employees

5,535

N/A

Net Income

€403.10M

+73.8%

EBITDA

€945.80M

+76.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€1.97B

+305.7%

Total Debt

€963.10M

+96.5%

Accounts Receivable

€999.39M

+39.0%

Inventory

€201.22M

-26.2%

Long Term Debt

€701.40M

+97.5%

Short Term Debt

€259.70M

+92.2%

Return on Assets

6.87%

N/A

Return on Invested Capital

21.29%

N/A

Free Cash Flow

€664.65M

+63.4%

Operating Cash Flow

€693.61M

+48.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
JAZZJazz Pharmaceuticals plc
$218.42-1.81%
EXELExelixis, Inc.
$59.86+1.42%
TGTXTG Therapeutics, Inc.
$55.37+3.81%
ESAIYEisai Co., Ltd.
$7.29-1.31%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About IPSEY

What is the current price of Ipsen?

Ipsen is trading at $40.65 per share.

What is the 52-week range for Ipsen?

Over the past 52 weeks, Ipsen has traded between $32.68 and $51.10.

How much debt does Ipsen have?

As of the most recent reporting period, Ipsen reported total debt of €1.14B.

How much cash does Ipsen have on hand?

Ipsen reported €1.79B in cash and cash equivalents in its most recent financial results.

What is Ipsen’s dividend yield?

Ipsen currently has a dividend yield of 1.13%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services